Last reviewed · How we verify
NCT04308616: SCCAPSO
Utility of Squamous Cell Carcinoma Antigen (SCCA) in Psoriasis
trial testing Blood samples in Psoriasis in 51 participants. Completed in 27 April 2022.
27 April 2022
Quick facts
| Lead sponsor | University Hospital, Tours |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 51 |
| Start date | 20 July 2020 |
| Primary completion | 27 April 2022 |
| Estimated completion | 27 April 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- Blood samples — full drug profile →
Conditions studied
- Psoriasis — all drugs for Psoriasis →
Sponsor
University Hospital, Tours
Who can join
18 and older, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Squamous Cell Carcinoma Antigen (SCCA) contributes to the pathogenesis of psoriasis by inhibiting cell apoptosis, exacerbating epidermal hyperplasia and skin inflammation. Three studies have shown a correlation between blood levels of SCCA and the severity of psoriasis. Clinical scores of psoriasis severity are used in consultation to guide treatment of the disease (initiation of systemic therapy, dose escalation) but they suffer from several pitfalls: lack of inter- and intra-observer reproducibility, consumption of medical time. A readily available, inexpensive (24 euros) blood marker could be an interesting alternative to these clinical scores.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04308616
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood samples
Trials testing the same drug.
- NCT07460700 — Mesenteric Ischemia Markers Study · NA · recruiting
- NCT06996249 — Prospective Data Collection Initiative on Thoracic Malignancies · recruiting
- NCT06694363 — New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome · recruiting
- NCT06826066 — Involvement of the Immune System in Intrinsic Radiosensitivity · NA · recruiting
- NCT06864481 — Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis · recruiting
Other recruiting trials for Psoriasis
Currently open trials in the same condition.
- NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
- NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
- NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
- NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
- NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting
Other University Hospital, Tours trials
Trials by the same sponsor.
- NCT07452978 — Propranolol for Early Secondary Prevention of Post-Traumatic Stress Disorder in Women Victims of Sexual Violence · Phase 2 · not yet recruiting
- NCT07443800 — Comorbidity Between Attention Deficit Hyperactivity Disorder and Fibromyalgia · NA · not yet recruiting
- NCT07251530 — Communication Enhancement Among Ventilated Patients in Intensive Care · not yet recruiting
- NCT07189338 — Apneic Oxygenation With High-flow Nasal Oxygenation After Preoxygenation With Noninvasive Ventilation Before Intubation · NA · not yet recruiting
- NCT07054112 — Efficacy of Live Online Course Mindfulness Program on Perceived Fatigue in Hemodialysis Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04308616 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Tours
- Last refreshed: 1 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04308616.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing